Drug Pipeline

Acasunlimab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Phase 3

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-06-12	NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to…	Trial terminated
2026-06-12	NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to…	date change Primary completion moved earlier: 2027-07-15 -> 2026-05-15
2026-06-12	NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to…	date change Completion moved earlier: 2029-07-15 -> 2026-05-15

Active Studies by Phase

Phase 3

Phase 2

Phase 1/2

Active Trials

NCT ID	Title	Condition	Status
Phase 3
NCT06635824	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of…	PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	Active, Not Recruiting
Phase 2
NCT05117242	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With…	Non Small Cell Lung Cancer Metastatic	Active, Not Recruiting
Phase 1/2
NCT03917381	GEN1046 Safety Trial in Patients With Malignant Solid Tumors	Solid Tumors	Active, Not Recruiting

Sponsors Running Acasunlimab Trials

Genmab (3)

Disease Areas

Get alerts when Acasunlimab trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.